Credit Hours: CME 1.25

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

Improve therapeutic skills for the use of Nocturnal Oxygen in Chronic Obstructive Pulmonary Patients.
Follow new pharmacologic treatments for excessive daytime sleepiness in Obstructive Sleep Apnea.
Improve therapeutic skill for management of chronic insomnia using behavioral therapy
Review COVID19 molecular and imaging diagnosis
Explain different modalities to provide respiratory support in patients with COVID19
Describe host-response therapeutics for COVID19
Describe a new treatment for hypereosinophilic syndrome
Analyze the efficacy of omalizumab in treatment of nasal polyposis
Assess the efficacy of dupilumab in treatment of nasal polyposis
Review the recommended guidelines for pulmonary arterial hypertension diagnosis and treatment
Explain new therapeutics in pulmonary arterial hypertension

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested additional reading:

Lacasse, Yves et al. “Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease.” The New England journal of medicine vol. 383,12 (2020): 1129-1138. doi:10.1056/NEJMoa2013219.
Dauvilliers, Yves et al. “Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.” American journal of respiratory and critical care medicine vol. 201,9 (2020): 1135-1145. doi:10.1164/rccm.201907-1284OC.
Morin, Charles M et al. “Effectiveness of Sequential Psychological and Medication Therapies for Insomnia Disorder: A Randomized Clinical Trial.” JAMA psychiatry, vol. 77,11 1–9. 8 Jul. 2020
RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436.
The REMAP-CAP investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report. MedRxiv.
Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. doi:10.1016/S0140-6736(20)32656-8. PMID: 33428867.
Shomali, W., & Gotlib, J. (2019). World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. American journal of hematology, 94(10), 1149-1167.
Kim, Christine, et al. "Role of biologics in chronic rhinosinusitis with nasal polyposis: state of the art review." Otolaryngology–Head and Neck Surgery (2020)
Anderson III, William C., and Stanley J. Szefler. "Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?." Annals of Allergy, Asthma & Immunology 122.4 (2019): 367-372.
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801913.
Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan 24;53(1):1801889.
Galiè N, Barberà JA, Frost AE, et al; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44.

Joint Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:

Andrej A. Petrov, MD — Pulmonary, Allergy and Critical Care Medicine, Associate Professor of Medicine, Section Chief of Allergy, University of Pittsburgh School of Medicine
Dr. Petrov is a consultant with CSL Behring, Takeda, and Pharming.

Belinda N Rivera-Lebron, MD, MSCE — Pulmonary, Allergy and Critical Care Medicine, Associate Professor of Medicine, Director, UPMC Acute Pulmonary Embolus (PE) Program, Director, UPMC Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program, University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.

Georgios Kitsios, MD, PhD — Pulmonary, Allergy and Critical Care Medicine, Assistant Professor of Medicine, Director, American Board of Internal Medicine (ABIM) Research Pathway, Internal Medicine Residency Program, UPMC
Dr. Kitsios receives grant/research funds from Karius, Inc.

Mazen El Ali, MD — Pulmonary, Allergy and Critical Care Medicine, Clinical Assistant Professor of Medicine, Director, Sleep Medicine Fellowship Program University of Pittsburgh
No relationships with industry relevant to the content of this educational activity have been disclosed.

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.